Conclusion
SOLID TUMORS
Fruquintinib was generally well tolerated in these patients, with a safety profile consistent with that of other studies conducted in China. The RP2D in U.S. patients is the same as the approved dose in China, and PK characteristics are consistent with those in the dose-finding study conducted in China. Preliminary anticancer activity was evident in these patients with advanced solid tumors. Based on the results of this phase 1/1b study and earlier studies, further investigation of fruquintinib in patients with mCRC was conducted in a global phase 3 study along with a phase 1b/2 study of fruquintinib in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with solid tumors.